PEG Ratio: 7.03
Is the PEG ratio high or low?
The PEG ratio of 7.03 is 72% above its 5-year average of 4.08, around the middle of its 5-year range (0.05–14.62).
EW PEG Ratio Chart
Reported annual fiscal-period values; no daily interpolation.
EW Average PEG Ratio Chart
EW Current vs Average PEG Ratio Chart
EW PEG Ratio Metrics
PEG RATIO
7.03
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
5.11
PEG RATIO AVG 5Y
4.08
PEG RATIO AVG 10Y
3.13
PEG RATIO AVG 15Y
1.49
PEG RATIO AVG 20Y
1.28
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+37.66%
CURRENT VS 5Y AVG
+72.30%
CURRENT VS 10Y AVG
+124.33%
CURRENT VS 15Y AVG
+373.26%
CURRENT VS 20Y AVG
+449.22%
EW Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 7.03 | N/A | 5.11 | 4.08 |
| Cencora, Inc. (COR)vs › | $55.67B | 7.05 | 7.05 | 4.17 | 3.13 |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 0.30 | 0.23 | 0.17 | 0.13 |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 2.43 | 1.76 | 0.97 | 0.68 |
| Humana Inc. (HUM)vs › | $46.08B | N/A | 0.45 | 0.32 | 0.59 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 2.31 | 4.41 | 3.66 | 3.13 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 3.38 | 2.53 | 2.53 | 1.33 |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 0.88 | 2.57 | 1.84 | 2.46 |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 9.44 | 7.54 | 13.88 | 11.22 |
| Medline Inc. (MDLN)vs › | $32.87B | N/A | 0.07 | 0.07 | 0.07 |
Growth-Adjusted Valuation
PEG Ratio
7.03
P/E Ratio
48.3
PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
PEG Ratio FAQ
- What is the PEG ratio for Edwards Lifesciences Corporation (EW)?
- The PEG ratio for EW stock is 7.03.
- Is Edwards Lifesciences Corporation's PEG ratio high or low?
- The PEG ratio of 7.03 is 72% above its 5-year average of 4.08, around the middle of its 5-year range (0.05–14.62).
- What is the 3Y average PEG ratio for Edwards Lifesciences Corporation (EW)?
- The 3Y average PEG ratio for EW stock is 5.11.
- What is the 5Y average PEG ratio for Edwards Lifesciences Corporation (EW)?
- The 5Y average PEG ratio for EW stock is 4.08.
- What is the 10Y average PEG ratio for Edwards Lifesciences Corporation (EW)?
- The 10Y average PEG ratio for EW stock is 3.13.
- What is the 15Y average PEG ratio for Edwards Lifesciences Corporation (EW)?
- The 15Y average PEG ratio for EW stock is 1.49.
- What is the 20Y average PEG ratio for Edwards Lifesciences Corporation (EW)?
- The 20Y average PEG ratio for EW stock is 1.28.
EW PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.05 |
| 2022-12-31 | 14.62 |
| 2021-12-31 | 0.65 |
| 2019-12-31 | 1.00 |
| 2018-12-31 | 2.56 |
| 2017-12-31 | 3.79 |
| 2016-12-31 | 2.25 |
| 2014-12-31 | 0.15 |
| 2013-12-31 | 0.50 |
| 2012-12-31 | 1.53 |
| 2011-12-31 | 3.59 |
| 2009-12-31 | 0.27 |
| 2008-12-31 | 1.29 |
| 2006-12-31 | 0.28 |
| 2005-12-31 | 0.01 |
| 2003-12-31 | 0.56 |
| 2001-12-31 | 1.42 |
| 2000-12-31 | 0.01 |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian